JT Lear, MT Atherton, JPH Byrne Summary Pyoderma gangrenosum and Sweet's syndrome are classified as neutrophilic dermatoses as they exhibit intense dermal inflanumatory infiltrates composed of neutrophils with little evidence of a primary vasculitis. They share several characteristics and respond to immunosuppressives. Aetiology is felt to represent a manifestation of altered immunologic reactivity. Patients with both conditions concurrently have been described. Diagnosis is based on clinical and histopathological findings. However, clinically the typical forms of the two conditions are quite distinct: pyoderma showing cutaneous ulceration with a purple undermined border and Sweet's syndrome having tender, erythematous, nonulcerated plaques and nodules. Approximately 50% of cases of pyoderma are associated with a specific systemic disorder. These include inflammatory bowel disease, rheumatoid arthritis, non-Hodgkin's lymphoma and myeloproliferative disorders. Many associations with Sweet's syndrome have been described, including acute myeloid leukaemia, myeloma and adenocarcinomas, and haematological malignancy. There is overlap between the two conditions with lesions categorised as Sweet's syndrome being clinically more characteristic of atypical pyoderma and vice versa. We believe that pyoderma and Sweet's syndrome represent a continuum of spectrum of disease. The reason for the clinical differences between the conditions is unclear and merits further investigation but may be explained by varying levels of intensity and extent ofthe inflammatory process. This review will describe the pathogenesis, clinical features, diagnosis, associations and treatment of the two conditions. Keywords Like pyoderma gangrenosum the pathogenesis is unknown. There can be a preceding infection especially upper respiratory tract or it can occur following vaccination.4 Antineutrophil cytoplasmic antibodies can be found but this is probably an epiphenomenon. They may be useful diagnostically in that they appear to be absent in other conditions that may cause clinical or histological confusion.7 Some authors have suggested the condition may be an unusual tissue reaction to an unknown allergen.7 Neutrophil abnormality studies are conflicting, with some studies showing enhanced chemotaxis8 and others reduced.9 Interleukin 1 has been postulated as a chemoattractant.10 Also, as seen in pyoderma gangrenosum, Sweet's syndrome appearing after granulocyte colony stimulating factor administration has been reported, suggesting that granulocyte colony stimulating factor may exacerbate a pre-existing autoimmune inflammatory condition by stimulating neutrophil proliferation and activity at sites of chronic inflammation.6 It seems that, like pyoderma gangrenosum, the immune system has a major role in the pathogenesis of Sweet's syndrome. 
